RecruitingNCT06363435

AI-based Measurements of Tumour Burden in PSMA PET-CT

The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer

Sponsor

Elin Tragardh

Enrollment

1,500 participants

Start Date

Mar 29, 2024

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer

Summary

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).

Eligibility

Sex: MALEMin Age: 20 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This study uses artificial intelligence (AI) to automatically measure the amount of cancer in the body (called "tumor burden") on a specific type of PET scan used for prostate cancer. The goal is to see if AI measurements are as accurate as human expert measurements. **You may be eligible if...** - You are a patient who has been referred for a PSMA PET-CT scan (a specialized nuclear medicine scan for prostate cancer) at Skåne University Hospital in Sweden - You are 20 years old or older **You may NOT be eligible if...** - You are under 20 years old Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans

Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients

Locations(2)

Skåne University Hospital

Lund, Sweden

Skåne university hospital

Malmö, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06363435

Related Trials

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations